The short version
- Signed April 18, 2026, directing agencies to speed research, review, and access to psychedelic treatments for serious mental illness.
- HHS is directed to commit at least $50 million to states developing psychedelic treatment programs.
- The FDA announced priority vouchers for three psychedelic drugs and a path for the first U.S. human ibogaine trials.
- It directs the DEA to move quickly on rescheduling psychedelic treatments that complete Phase 3.
What happened
On April 18, 2026, President Trump signed an executive order directing federal agencies to accelerate research, regulatory review, and access to psychedelic drugs for serious mental illness. Health Secretary Robert F. Kennedy Jr., podcaster Joe Rogan, and retired Navy SEAL Marcus Luttrell were in the Oval Office for the signing.1
What's in it
| Provision | Details |
|---|---|
| State funding | HHS to commit at least $50 million to states developing psychedelic treatment programs1 |
| FDA priority vouchers | FDA Commissioner Marty Makary announced national priority vouchers for three psychedelics to speed review1 |
| Ibogaine | FDA clearing a pathway for the first U.S. human trials of ibogaine1 |
| DEA rescheduling | Directs the DEA to review psychedelic treatments that complete Phase 3 so rescheduling can happen as quickly as possible2 |
What it means for psilocybin
Psilocybin is the most direct beneficiary. Compass Pathways' COMP360 has already completed two Phase 3 trials, holds an FDA Commissioner's National Priority Voucher, and is the clearest candidate for the order's rescheduling directive.2 If the FDA approves it, the order is meant to keep the DEA from becoming the bottleneck.
The order also changed the mood. Within three months, Eli Lilly agreed to buy psychedelic developer AtaiBeckley for $2.8 billion, and HHS and the VA signed an agreement on psychedelic treatments for veterans.34 Executive orders can't approve drugs, but they can signal to investors and agencies which way the wind is blowing.
The ibogaine controversy
A lot of the order's energy goes to ibogaine, a psychedelic from the iboga shrub that's being studied for opioid addiction. It's also the most medically risky drug in the group. Ibogaine can cause dangerous heart rhythm problems and has been linked to more than 30 deaths in the medical literature.1 Researchers like Johns Hopkins' Frederick Barrett have acknowledged its known cardiotoxicity while supporting rigorous research.1 Supporters argue that for people facing the opioid crisis, the risk is worth studying carefully under medical supervision. Critics worry political enthusiasm could get ahead of the safety data.
What it doesn't do
- It doesn't legalize psilocybin or reschedule it. Mushrooms remain Schedule I.
- It doesn't approve any drug. The FDA still has to review the evidence.
- It doesn't override state laws.
For the current legal picture, see are shrooms legal?
Sources
- Associated Press via WSLS. Trump signs order to speed review of psychedelics, including the controversial drug ibogaine. April 18, 2026. wsls.com
- Compass Pathways. First quarter 2026 financial results and business highlights (Form 8-K). 2026. sec.gov
- Becker's Behavioral Health. Eli Lilly to acquire psychedelic drug developer for $2.8B. July 2026. beckersbehavioralhealth.com
- U.S. Department of Health and Human Services. HHS, VA partner to advance psychedelic therapies for veterans. July 13, 2026. hhs.gov
This article is for education only and is not medical or legal advice. Psilocybin is a Schedule I substance under U.S. federal law. Talk with a licensed clinician before making decisions about your health. In a crisis, call or text 988.